Medical 21 received $2.5 million at the close of the investment, and the investor has the option to invest another $2.5 million every 10 months. The capital will be used to develop Medical 21’s artificial graft technology for an upcoming FDA early feasibility study, according to the Sept. 20 Medical 21 news release.
Medical 21 will continue crowdfunding through its $40 million regulation A+ equity offering. Medical Funding Professionals and Life Science Intelligence are providing strategic guidance to Medical 21 throughout the company’s fundraising.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
